Scientists at the University of Pittsburgh School of Medicine found a missing piece in the puzzle of how melanoma tumors stay alive and keep growing.
Telomeres Guard the Ends of DNA
Telomeres are tiny caps that sit at the ends of our chromosomes. They protect DNA from breaking. Every time a normal cell splits, the telomeres get a little shorter. When they become too short, the cell stops dividing.
If telomeres shrink too fast, people can age early or die young. If telomeres stay very long, cancer can appear. Melanoma cells are known for having unusually long telomeres.
The Role of Telomerase and TERT
Telomerase is an enzyme that lengthens telomeres. Healthy cells usually keep telomerase turned off. Many cancers turn it on by mutating the TERT gene, which makes telomerase work nonstop.
About three‑quarters of melanoma tumors have TERT mutations that boost telomerase. Yet scientists could not reproduce the super‑long telomeres of melanoma just by adding TERT mutations to normal skin cells. Something else was missing.
Finding the Missing Piece: TPP1
Pattra Chun‑on, a researcher in Dr. Alder’s lab, looked at cancer mutation databases and saw frequent changes in a protein called TPP1. These changes were in a newly found promoter region and made the cell produce more TPP1.
Earlier lab work had shown that TPP1 helps telomerase work better, but nobody had proved it in real tumors. When Chun‑on added both the mutated TERT and the mutated TPP1 to cells, the telomeres grew as long as those in melanoma tumors.
In other words, TPP1 was the missing factor that completed the telomere‑lengthening puzzle.
Why This Matters
The discovery explains how melanoma becomes immortal and keeps dividing. It also reveals a new, cancer‑specific system that could be targeted by future medicines.
Scientists hope that drugs designed to block the TPP1‑telomerase partnership might stop melanoma cells from living forever.